TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01251562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Compound C31510 for Injection
Description: During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Compound C31510 for Injection
Description: During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Compound C31510 for Injection
Description: During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Compound C31510 for Injection
Description: During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
Study: NCT01109069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: Dose based on parent protocol
Study: NCT02818413

Intervention type: OTHER
Intervention: Biospecimen collection and questionnaires
Description: Biospecimen collection and questionnaires
Study: NCT01251562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Compound C31510 for Injection
Description: During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
Study: NCT03457766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: Ultrasound (Esaota MyLabSeven) imaging system using (SL2325) probe with (6-19 MHz) frequency
Study: NCT02953613

Intervention type: DEVICE
Intervention: NIRS/IVUS
Description: Cardiac catheterization using infraredx
Study: NCT01251562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Compound C31510 for Injection
Description: During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Compound C31510 for Injection
Description: During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
Study: NCT03927911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL and Bupivacaine
Description: Drug: EXPAREL and Bupivacaine HCl 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL and Bupivacaine
Description: Drug: EXPAREL and Bupivacaine HCl 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL and Bupivacaine
Description: Drug: EXPAREL and Bupivacaine HCl 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT04589962

Intervention type: OTHER
Intervention: access axillary or brachial artery
Description: access to the axillary or brachial artery during Transcatheter Aortic Valve Implantation (TAVI), Fenestrated/Branched-Endovascular Aortic Repair (F/BEVAR), chimney-EVAR (Ch-EVAR) or visceral side branches stenting

Intervention type: OTHER
Intervention: access axillary or brachial artery
Description: access to the axillary or brachial artery during Transcatheter Aortic Valve Implantation (TAVI), Fenestrated/Branched-Endovascular Aortic Repair (F/BEVAR), chimney-EVAR (Ch-EVAR) or visceral side branches stenting
Study: NCT00562640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
Study: NCT02560493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming Condition
Description: Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
Study: NCT01952704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
Study: NCT02658968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betalutin
Description: Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
Study: NCT01354613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dobutamine
Description: IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
Study: NCT01163396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/leucovorin
Study: NCT04001439

Intervention type: DRUG
Group type: OTHER
Intervention: Experimental drug
Description: All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
Study: NCT00994825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%
Study: NCT00921115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole
Description: Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
Study: NCT02025634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen
Description: Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% Normal Saline infusion)
Description: Infusion of 100 ml of 0.9% NS
Study: NCT01218217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 150 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 150 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 150 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 150 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 150 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 150 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 150 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 150 mg capsules
Study: NCT04593368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT
Description: oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
Study: NCT03023306

Intervention type: OTHER
Group type: OTHER
Intervention: Antiemetics perioperatively
Description: Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiemetics perioperatively
Description: Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
Study: NCT02270658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Study: NCT03929354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Factors Modification Programme
Description: 12-week supervised risk factor modification programme derived from the EuroAction Study standards.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients advised to adjust lifestyle without the support of the structured supervised programme.
Study: NCT01198782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)
Description: Patients will dose 4 times daily for 4 months.
Study: NCT04169646

Intervention type: OTHER
Group type: OTHER
Intervention: Multi-component intervention
Description: Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention takes place during the control phase.
Study: NCT03599518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1205c
Description: DS-1205c 200 mg capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg tablet for oral administration
Study: NCT03884153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP apheresis
Description: selective CRP apheresis by use of the PentraSorb-CRP
Study: NCT02790840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20 mg oral capsules administered once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg oral capsules administered twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
Study: NCT00532129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: 10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
Study: NCT04725045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific: Study tool computer
Description: compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
Study: NCT01354613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
Study: NCT04725045

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific: Study tool computer
Description: compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
Study: NCT03005730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phototherapy
Description: The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: phototherapy placebo
Description: The placebo portable. The aperture size of device is 4 cm2 .
Study: NCT00429143

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI twice daily days 6-9 prior to transplant (HSCT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: DLI given 6 days prior to transplant (HSCT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus given one day prior to transplant (HSCT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: MMF given one day prior to transplant (HSCT).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant (HSCT)
Description: CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
Study: NCT02824393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cell
Description: Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
Study: NCT01741493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: Oral administration of ABT-494 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: Oral administration of ABT-494 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Tofacitinib
Description: Oral administration
Study: NCT02948764

Intervention type: DEVICE
Group type: OTHER
Intervention: Vacuum-Assisted Biopsy
Description: The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, or by mammography (stereotaxy) during the second trial visit (V2) will be performed once. In analogy to the German S3 guideline on primary breast cancer management we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes.
Study: NCT02681367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze all policy
Description: Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
Study: NCT03134859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tummy Time
Description: deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tummy Time
Description: deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tummy Time
Description: deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
Study: NCT01504295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metadoxine
Description: Improve Liver Function and Reduce ALcohol Use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metadoxine
Description: Improve Liver Function and Reduce ALcohol Use
Study: NCT00666081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK690693
Description: Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.